| 11/08/20 | SUPN | SPN-812 (NDA) | FDA decision on SPN-812 for the treatment of ADHD |
| 10/30/20 | KALA | EYSUVIS 0.25% (Resubmitted NDA) | FDA decision on EYSUVIS 0.25% for Dry Eye Disease |
| 10/30/20 | MRK | KEYTRUDA (sBLA) | FDA decision on KEYTRUDA as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma |
| 10/25/20 | REGN | REGN-EB3 (BLA) | FDA decision on REGN-EB3 for Ebola virus infection |
| 10/24/20 | SPPI | ROLONTIS (BLA) | FDA decision on ROLONTIS for the treatment of chemotherapy-induced neutropenia |
| 10/20/20 | ZSAN | Qtrypta (NDA) | FDA decision on Qtrypta for the acute treatment of Migraine |